TickerHumNYSE · Healthcare · Drug Manufacturers—General
Bristol-Myers Squibb Company (BMY)
As of Nov 11, 4:00 PM ET, Bristol-Myers Squibb (BMY) last traded at $62.91, up 0.18% on the day. Its TickerHum research score is 69/100 (above average). It reported revenue of $50.03B for the twelve months ending 2026-09-30, up 4.2% year over year.
Ratings
- Valuation: 92/100 — Based on price / earnings (ttm) 13.9x, price / sales (ttm) 2.6x, free-cash-flow yield 7.2 %.
- Growth: 68/100 — Strongest input: diluted eps growth (ttm, yoy) +51.9 %. Weakest: revenue growth (ttm, yoy) +4.2 %.
- Profitability: 86/100 — Strongest input: return on equity 39.5 %. Weakest: net margin 18.5 %.
- Financial health: 32/100 — Strongest input: current ratio 1.59. Weakest: cash / long-term debt 0.23.
- Momentum: 57/100 — Strongest input: 1-year return +28.2 %. Weakest: 3-month return -2.7 %.
- Attention: 52/100 — Strongest input: headlines in the last 7 days 28. Weakest: volume vs 3-month average 0.6x.
- Risk resilience: 80/100 — Strongest input: annualised volatility (1y) 27.8 %. Weakest: max drawdown (1y) -16.8 %.
- Data confidence: 97/100 — Strongest input: quote age (hours) 6 h. Weakest: inputs available 90 %.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $50.03B | TTM ending 2026-09-30 · 10-Q |
| Revenue growth | 4.2% | TTM ending 2026-09-30 · 10-Q |
| Net income | $9.24B | TTM ending 2026-09-30 · 10-Q |
| Diluted EPS | $4.51 | TTM ending 2026-09-30 · 10-Q |
| Net margin | 18.5% | TTM ending 2026-09-30 · 10-Q |
| Free cash flow | $9.29B | TTM ending 2026-09-30 · 10-Q |
| Cash | $9.57B | as of 2026-09-30 · 10-Q |
| Long-term debt | $41.85B | as of 2026-09-30 · 10-Q |
| Debt / equity | 1.79 | as of 2026-09-30 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000014272).
Comparable companies for Bristol-Myers Squibb
Selected by industry, business overlap and scale; these are not necessarily direct competitors.
- Bristol-Myers Squibb vs AbbVie (BMY vs ABBV) — Same industry (Drug Manufacturers—General); market cap 4.1x; shares: immunology, oncology
- Bristol-Myers Squibb vs Pfizer (BMY vs PFE) — Same industry (Drug Manufacturers—General); market cap 1.3x; shares: oncology
- Bristol-Myers Squibb vs Gilead Sciences (BMY vs GILD) — Same industry (Drug Manufacturers—General); market cap 1.6x; shares: oncology
- Bristol-Myers Squibb vs Amgen (BMY vs AMGN) — Same industry (Drug Manufacturers—General); market cap 2.0x; shares: oncology
- Bristol-Myers Squibb vs Merck & Co. (BMY vs MRK) — Same industry (Drug Manufacturers—General); market cap 2.8x; shares: oncology
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.